Zai Lab Ltd. 2025 Q2 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Zai Lab Ltd. is a commercial-stage biopharmaceutical company focused on oncology, immunology, neuroscience, and infectious diseases, with principal operations in Greater China and the United States. The company operates as a single segment and is currently in a cumulative loss position.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $109.98 million | $216.46 million | $100.50 million | $187.65 million |
| Net Loss | ($40.73 million) | ($89.17 million) | ($80.28 million) | ($133.75 million) |
| Loss Per Share (Basic/Diluted) | ($0.04) | ($0.08) | ($0.08) | ($0.14) |
| Operating Cash Flow | N/A | ($92.72 million) | N/A | ($132.28 million) |
| Cash & Equivalents (End of Period) | $732.16 million | $732.16 million | N/A | N/A |
| Total Liquidity (Cash + Restricted + ST Inv) | $832.27 million | $832.27 million | N/A | N/A |
| Short-Term Debt | $174.51 million | $174.51 million | N/A | N/A |
Note: Short-term investments were $0 as of June 30, 2025, down from $330 million at year-end 2024, due to maturities.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 9% in Q2 and 15% YTD compared to 2024. Product revenue grew 9% in Q2, driven by higher sales of VYVGART (14% increase), NUZYRA (16% increase), and new launches XACDURO and AUGTYRO. This was partially offset by a 9% decline in ZEJULA sales due to competitive dynamics.
- Expense Reduction: Net loss improved significantly (49% reduction in Q2, 33% YTD). Research and Development (R&D) expenses decreased 18% in Q2 and 4% YTD, primarily due to reduced personnel costs and CRO/CMO fees. Selling, General, and Administrative (SG&A) expenses decreased 11% in Q2 and 10% YTD.
- One-Time Costs: YTD 2025 R&D included a $20.0 million increase in licensing fees, including a $10.0 million upfront fee for a license agreement with Zenas BioPharma.
- Debt Levels: Short-term debt increased to $174.5 million from $131.7 million at year-end 2024 to support working capital needs.
Guidance, Outlook, and Risks
- Pipeline Progress:
- ZL-1310 (DLL3 ADC): Received FDA Fast Track designation for ES-SCLC; positive Phase Ia/Ib data presented at ASCO 2025. Pivotal trial planned for late 2025.
- Bemarituzumab: Met primary endpoint (Overall Survival) in Phase III FORTITUDE-101 trial for gastric cancer. Regulatory filing in China planned for H2 2025.
- TTFields (OPTUNE): Partner NovoCure reported positive Phase III PANOVA-3 results for pancreatic cancer. Filing in China planned for H2 2025.
- Repotrectinib: NMPA accepted supplemental NDA for NTRK+ solid tumors in April 2025.
- Liquidity Outlook: Management expects current cash and liquidity resources ($832.3 million) to fund operations for at least the next 12 months. The company has access to additional credit facilities totaling approximately $240.2 million.
- Risks: Key risks include the ability to successfully commercialize products, regulatory approval timelines, reliance on third-party CROs/CMOs, and geopolitical/regulatory risks associated with operations in mainland China (including foreign exchange controls and data security laws).
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of VYVGART and NUZYRA growth trends versus the decline in ZEJULA.
- Cost Management: Assess whether the reduction in R&D and SG&A personnel costs impacts the speed of clinical development or commercial execution.
- Debt Covenants: Review the terms of the new RMB500 million credit facility with China Merchants Bank (CMB) entered into in August 2025 for restrictive covenants.
- Regulatory Milestones: Monitor the timing of regulatory filings for Bemarituzumab and TTFields in China for H2 2025.
- Cash Burn Rate: Confirm the trajectory of operating cash burn relative to the $832 million liquidity buffer.